Recently, biotechnological engineering of dendritic cells enabled the generation of bispecific EVs co-expressing anti-CD19 scFv and PD1, thereby combining tumor antigen targeting with immune checkpoint blockade [50]. The gene discussed is CD19; the disease is neoplasm.